Trial · NCT07205107
Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Triple Combination Gel in Canadian Patients With Acne Vulgaris
NCT07205107, Completed, Bausch Health Americas, Inc.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Triple Combination Gel in Canadian Patients With Acne Vulgaris. Trials, record NCT07205107. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07205107
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Triple Combination Gel in Canadian Patients With Acne Vulgaris
- NCT number
- NCT07205107
- Status
- Completed
- Enrollment
- 200 participants, actual
- Lead sponsor
- Bausch Health Americas, Inc.
- Conditions
- Acne Vulgaris
- Interventions
- clindamycin phosphate, adapalene and benzoyl peroxide
- First posted
- 2025-10-03
- Last updated
- 2026-09-09
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Treatment Satisfaction at Week-12 as assessed by DermSat-7 | Week 12 | To describe treatment satisfaction of clindamycin phosphate 1.2% / adapalene 0.15% / benzoyl peroxide 3.1% gel at Week-12 in patients with acne vulgaris in Canadian routine clinical practice, using mean DermSat-7 domain scores. The DermSat-7 is a dermatology-specific, 7-item questionnaire used to assess patient satisfaction with treatment across three domains: effectiveness, convenience, and overall satisfaction. Domain scores are transformed to a linear 0-100 scale, with higher scores indicating greater satisfaction. |
| Secondary | Treatment Satisfaction at Week-4, Week-8 and Week-20 as assessed by DermSat-7 | Week 4, Week 8 and Week 20 | To describe treatment satisfaction of clindamycin phosphate 1.2% / adapalene 0.15% / benzoyl peroxide 3.1% gel at Week-4, Week-8 and Week-20 in patients with acne vulgaris in Canadian routine clinical practice, using mean DermSat-7 domain scores. The DermSat-7 is a dermatology-specific, 7-item questionnaire used to assess patient satisfaction with treatment across three domains: effectiveness, convenience, and overall satisfaction. Domain scores are transformed to a linear 0-100 scale, with higher scores indicating greater satisfaction. |
| Secondary | Change from Baseline in Treatment Satisfaction at Week-12 as assessed by DermSat-7 | Baseline and Week-12 | To describe change in treatment satisfaction at Week-12 following clindamycin phosphate 1.2% / adapalene 0.15% / benzoyl peroxide 3.1% gel initiation in patients with acne vulgaris in Canadian routine clinical practice, using mean DermSat-7 domain scores. The DermSat-7 is a dermatology-specific, 7-item questionnaire used to assess patient satisfaction with treatment across three domains: effectiveness, convenience, and overall satisfaction. Domain scores are transformed to a linear 0-100 scale, with higher scores indicating greater satisfaction. |
| Secondary | Treatment Adherence at Week-4, Week-8, Week-12, and Week-20 | From Baseline to Week-20 | To describe treatment adherence to clindamycin phosphate 1.2% / adapalene 0.15% / benzoyl peroxide 3.1% gel in patients with acne vulgaris in Canadian routine clinical practice, as captured in a daily electronic diary using percentage of patients who achieve at least 80% treatment adherence at Week-4, Week-8, Week-12, and Week-20 from treatment initiation. |
| Secondary | Treatment Effectiveness as assessed by mean change from baseline in Investigator Global Assessment (IGA) score | Baseline, Week-12, and Week-20 | To describe the effectiveness of clindamycin phosphate 1.2% / adapalene 0.15% / benzoyl peroxide 3.1% gel in patients with acne vulgaris in Canadian routine clinical practice, as assessed by mean change in IGA score at Week-12 and Week-20 from baseline. The IGA is a 5-point scale (0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, 4 = severe), with higher scores indicating worse acne severity. |
| Secondary | Treatment Effectiveness as assessed by mean Investigator Global Assessment (IGA) score | Baseline, Week-12, and Week-20 | To describe the effectiveness of clindamycin phosphate 1.2% / adapalene 0.15% / benzoyl peroxide 3.1% gel in patients with acne vulgaris in Canadian routine clinical practice, as assessed by mean IGA score at baseline, Week-12, and Week-20. The IGA is a 5-point scale (0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, 4 = severe), with higher scores indicating worse acne severity. |
| Secondary | Treatment Effectiveness as assessed by percentage of patients achieving at least a 1-grade improvement in Investigator Global Assessment (IGA) score | Baseline, Week-12, and Week-20 | To describe the effectiveness of clindamycin phosphate 1.2% / adapalene 0.15% / benzoyl peroxide 3.1% gel in patients with acne vulgaris in Canadian routine clinical practice, as assessed by the percentage of patients who have achieved at least a 1-grade improvement at Week-12 and Week-20 from baseline. The IGA is a 5-point scale (0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, 4 = severe), with higher scores indicating worse acne severity. |
| Secondary | Treatment Effectiveness as assessed by number and percentage of patients achieving a score of 0 to 1 in Investigator Global Assessment (IGA) score | Week-12, and Week-20 | To describe the effectiveness of clindamycin phosphate 1.2% / adapalene 0.15% / benzoyl peroxide 3.1% gel in patients with acne vulgaris in Canadian routine clinical practice, as assessed by number and percentage of patients who achieve IGA = 0 to 1 at Week-12 and Week-20. The IGA is a 5-point scale (0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, 4 = severe), with higher scores indicating worse acne severity. |
| Secondary | Safety and Tolerability | From baseline to Week-20 | To describe the safety and tolerability of clindamycin phosphate 1.2% / adapalene 0.15% / benzoyl peroxide 3.1% gel in patients with acne vulgaris in Canadian routine clinical practice, with number and percentage of adverse events (AEs) and serious AEs (SAEs) reported over 20 weeks, and number and percentage of patients who discontinued due to an AE or SAE at Week-20. |
| Secondary | Health State Utility as assessed by Health Utility Index 2 (HUI2) | Baseline, Week-12, and Week-20 | To describe the health state utility scores in patients with acne vulgaris treated with clindamycin phosphate 1.2% / adapalene 0.15% / benzoyl peroxide 3.1% gel in Canadian routine clinical practice, as per percentage change in Health Utility Index 2 (HUI2) score at Week-12 and Week-20 from baseline, and mean HUI2 score at baseline, Week-12, and Week-20. |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07205107
GET https://conductscience.org/api/trials/v1/NCT07205107/registered